No Data
Personalis and Tempus AI Extend Commercial Deal to Biopharma Industry
Express News | Personalis and Tempus Expand Collaboration to Biopharma
Insiders Own 36% of Tempus AI, Inc (NASDAQ:TEM) in Spite of Selling Recently and the Recent Dip May Have Hurt Them
With A 40% Price Drop For Tempus AI, Inc (NASDAQ:TEM) You'll Still Get What You Pay For
Insider Sale: EVP and General Counsel of $TEM (TEM) Sells 3,900 Shares
Tempus AI(TEM.US) Officer Sells US$3.94 Million in Common Stock